HRP20140073T1 - Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti - Google Patents

Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti Download PDF

Info

Publication number
HRP20140073T1
HRP20140073T1 HRP20140073TT HRP20140073T HRP20140073T1 HR P20140073 T1 HRP20140073 T1 HR P20140073T1 HR P20140073T T HRP20140073T T HR P20140073TT HR P20140073 T HRP20140073 T HR P20140073T HR P20140073 T1 HRP20140073 T1 HR P20140073T1
Authority
HR
Croatia
Prior art keywords
roflumilast
inhibitor
hmg
coa reductase
pharmaceutically acceptable
Prior art date
Application number
HRP20140073TT
Other languages
English (en)
Inventor
Stefan-Lutz Wollin
Andrea Wohlsen
Clemens Braun
Degenhard Marx
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of HRP20140073T1 publication Critical patent/HRP20140073T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Claims (34)

1. Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4-inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, dok inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol, te pritom prva količina i druga količina zajedno sastavljaju učinkovitu količinu za prevenciju ili liječenje upalne plućne bolesti.
2. Kombinirani proizvod, naznačen time, da sadrži sljedeće sastojke: (A) jednu količinu PDE4-inhibitora; (B) jednu količinu inhibitora reduktaze HMG-CoA; pri čemu prva količina i druga količina zajedno sastavljaju učinkovitu količinu za prevenciju ili liječenje upalne plućne bolesti, gdje svaki od sastojaka (A) i (B) je formuliran u mješavini s barem jednim farmaceutski prihvatljivim pomoćnim sredstvom, dok je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol.
3. Garnitura, naznačena time, da sadrži sljedeće sastojke: (A) farmaceutska formulacija koja uključuje jednu količinu PDE4-inhibitora u mješavini s barem jednim farmaceutski prihvatljivim pomoćnim sredstvom; (B) farmaceutska formulacija koja uključuje jednu količinu inhibitora reduktaze HMG-CoA u mješavini s barem jednim farmaceutski prihvatljivim pomoćnim sredstvom; pri čemu prva količina i druga količina zajedno sastavljaju učinkovitu količinu za prevenciju ili liječenje upalne plućne bolesti, dok je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol.
4. Farmaceutski sastav prema zahtjevu 1, naznačen time, da PDE4-inhibitor je ROFLUMILAST.
5. Farmaceutski sastav prema zahtjevu 1, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
6. Farmaceutski sastav prema bilo kojem od zahtjeva 1, 4 ili 5, naznačen time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN hemi-kalcij.
7. Farmaceutski sastav prema bilo kojem od zahtjeva 1, 4 ili 5, naznačen time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN natrij.
8. Farmaceutski sastav prema bilo kojem od zahtjeva 1, 4 ili 5, naznačen time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN.
9. Kombinirani proizvod prema zahtjevu 2, naznačen time, da PDE4-inhibitor je ROFLUMILAST.
10. Kombinirani proizvod prema zahtjevu 2, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
11. Kombinirani proizvod prema bilo kojem od zahtjeva 2, 9 ili 10, naznačen time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN hemi-kalcij.
12. Kombinirani proizvod prema bilo kojem od zahtjeva 2, 9 ili 10, naznačen time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN natrij.
13. Kombinirani proizvod prema bilo kojem od zahtjeva 2, 9 ili 10, naznačen time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN.
14. Garnitura prema zahtjevu 3, naznačena time, da PDE4-inhibitor je ROFLUMILAST.
15. Garnitura prema zahtjevu 3, naznačena time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
16. Garnitura prema bilo kojem od zahtjeva 3, 14 ili 15, naznačena time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN hemi-kalcij.
17. Garnitura prema bilo kojem od zahtjeva 3, 14 ili 15, naznačena time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN natrij.
18. Garnitura prema bilo kojem od zahtjeva 3, 14 ili 15, naznačena time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN.
19. Farmaceutski sastav prema bilo kojem od zahtjeva 1, 4, 5, 6, 7 ili 8, naznačen time, da je upalna plućna bolest odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
20. Farmaceutski sastav prema bilo kojem od zahtjeva 1, 4, 5, 6, 7 ili 8, naznačen time, da upalna plućna bolest je COPD.
21. Kombinirani proizvod prema bilo kojem od zahtjeva 2, 9, 10, 11, 12 ili 13, naznačen time, da je upalna plućna bolest odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
22. Kombinirani proizvod prema bilo kojem od zahtjeva 2, 9, 10, 11, 12 ili 13, naznačen time, da upalna plućna bolest je COPD.
23. Garnitura prema bilo kojem od zahtjeva 3, 14, 15, 16, 17 ili 18, naznačena time, da je upalna plućna bolest odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
24. Garnitura prema bilo kojem od zahtjeva 3, 14, 15, 16, 17 ili 18, naznačena time, da upalna plućna bolest je COPD.
25. Uporaba PDE4-inhibitora i inhibitora reduktaze HMG-CoA, naznačena time, da je za proizvodnju lijeka, posebno farmacetskog sastava prema izumu, za prevenciju ili liječenje upalne plućne bolesti, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol.
26. Uporaba PDE4-inhibitora i inhibitora reduktaze HMG-CoA, naznačena time, da je za proizvodnju dodatnog lijeka koji se daje uzastopno ili odvojeno uz prvi lijek, posebno kombiniranog proizvoda ili garniture prema izumu, za prevenciju ili liječenje upalne plućne bolesti, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol.
27. Uporaba prema zahtjevu 25 ili 26, naznačena time, da PDE4-inhibitor je ROFLUMILAST.
28. Uporaba prema zahtjevu 25 ili 26, naznačena time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
29. Uporaba prema bilo kojem od zahtjeva 25, 26, 27 ili 28, naznačena time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN hemi-kalcij.
30. Uporaba prema bilo kojem od zahtjeva 25, 26, 27 ili 28, naznačena time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN natrij.
31. Uporaba prema bilo kojem od zahtjeva 25, 26, 27 ili 28, naznačena time, da inhibitor reduktaze HMG-CoA je ROSUVASTATIN.
32. Uporaba prema bilo kojem od zahtjeva 25 do 31, naznačena time, da je upalna plućna bolest odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
33. Uporaba prema bilo kojem od zahtjeva 25 do 31, naznačena time, da upalna plućna bolest je COPD.
34. Postupak za proizvodnju farmaceutskog sastava prema bilo kojem od zahtjeva 1, 4, 5, 6, 7, 8, 19 ili 20, naznačen time, da obuhvaća miješanje PDE4-inhibitora ili njegove farmaceutski prihvatljive soli s inhibitorom reduktaze HMG-CoA ili s njegovom farmaceutski prihvatljivom soli.
HRP20140073TT 2006-07-05 2014-01-21 Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti HRP20140073T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06116625 2006-07-05

Publications (1)

Publication Number Publication Date
HRP20140073T1 true HRP20140073T1 (hr) 2014-02-28

Family

ID=37311957

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20140073TT HRP20140073T1 (hr) 2006-07-05 2014-01-21 Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti
HRP20140707TT HRP20140707T1 (hr) 2006-07-05 2014-07-22 KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20140707TT HRP20140707T1 (hr) 2006-07-05 2014-07-22 KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA

Country Status (26)

Country Link
US (2) US20100069392A1 (hr)
EP (3) EP2359826B1 (hr)
JP (3) JP5349302B2 (hr)
KR (1) KR101433394B1 (hr)
CN (3) CN101484166B (hr)
AT (1) ATE535244T1 (hr)
AU (1) AU2007271186C1 (hr)
BR (1) BRPI0713768A2 (hr)
CA (1) CA2656366A1 (hr)
CY (2) CY1114742T1 (hr)
DK (2) DK2363130T3 (hr)
EA (2) EA032476B1 (hr)
ES (3) ES2489265T3 (hr)
HR (2) HRP20140073T1 (hr)
IL (3) IL195433A (hr)
ME (2) ME01648B (hr)
MX (1) MX2008016123A (hr)
NO (1) NO342590B1 (hr)
NZ (3) NZ594369A (hr)
PL (2) PL2363130T3 (hr)
PT (2) PT2359826E (hr)
RS (2) RS53084B (hr)
SI (2) SI2363130T1 (hr)
UA (3) UA106422C2 (hr)
WO (1) WO2008003701A2 (hr)
ZA (1) ZA200809905B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI436767B (zh) * 2008-03-14 2014-05-11 Otsuka Pharma Co Ltd 基質金屬蛋白酶－２（ｍｍｐ－２）及／或基質金屬蛋白酶－９（ｍｍｐ－９）抑制劑
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
CA2953209A1 (en) * 2014-06-05 2015-12-10 Transgenion-International Institute For Regenerative Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
JP6755242B2 (ja) * 2014-06-05 2020-09-16 トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
JP6755241B2 (ja) * 2014-06-05 2020-09-16 トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021218988A1 (zh) * 2020-04-30 2021-11-04 中国科学院上海药物研究所 Prdx1激动剂及其用途
WO2024028388A1 (en) * 2022-08-03 2024-02-08 Chiesi Farmaceutici S.P.A. Dry powder inhaler

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60219A (en) 1979-06-15 1985-05-31 Merck & Co Inc Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
AU570021B2 (en) 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
EP0307342B1 (de) 1987-07-10 1996-01-03 Hoechst Aktiengesellschaft 3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
FR2642065B1 (fr) 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
CA2396738C (en) 1990-11-30 2006-08-29 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP1380571A1 (en) * 1992-04-02 2004-01-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
US6004974A (en) 1995-06-06 1999-12-21 Pfizer Inc Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
UA59443C2 (uk) 1998-04-28 2003-09-15 Арцнайміттельверк Дрезден Гмбх Гідроксііндол, спосіб його одержання, лікарська форма на його основі та спосіб її одержання
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
DE19944161A1 (de) 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
MY134008A (en) 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP2001294526A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd ＴＮＦ−α抑制剤
AU2001232245A1 (en) 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Tnf- alpha inhibitors
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US20050102317A1 (en) * 2000-07-21 2005-05-12 Ali Kamarei System and method for event calendaring using a customizable rules subset
CA2422820A1 (en) 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
EA200300836A1 (ru) * 2001-02-15 2004-02-26 Алтана Фарма Аг Производные фталазинон-пиперидина в качестве ингибиторов pde4
KR20100036390A (ko) * 2001-03-06 2010-04-07 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
JP4193435B2 (ja) * 2002-07-23 2008-12-10 ブラザー工業株式会社 インクカートリッジ、および、そのインク充填方法
AU2002257459B2 (en) * 2001-05-24 2006-12-14 Merck Frosst Canada Ltd 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
CA2450686A1 (en) * 2001-06-27 2003-01-09 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Substituted 8-arylquinoline pde4 inhibitors
US20030114469A1 (en) 2001-09-27 2003-06-19 Cohen David Saul Combinations
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EP1519922A1 (en) * 2002-07-02 2005-04-06 Merck Frosst Canada & Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
WO2004047829A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag New synergistic combination comprising roflumilast and formoterol
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040254238A1 (en) * 2003-04-07 2004-12-16 Osteoscreen Bone growth stimulation with NO/statin and other NO modulating combinations
DE602004020332D1 (de) 2003-04-11 2009-05-14 Glenmark Pharmaceuticals Sa Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
CN100441185C (zh) * 2003-04-30 2008-12-10 麦克弗罗斯特加拿大有限公司 8-(3-联芳基)苯基喹啉磷酸二酯酶-4抑制剂
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004103407A2 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2004110368A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
DE10348646A1 (de) 2003-10-15 2005-05-25 Gkn Driveline International Gmbh Rollbalg mit großem Krümmungsradius
CA2563693C (en) * 2004-04-19 2010-07-06 Loma Linda University Composition and method of decreasing renal ischemic damage
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0415789D0 (en) * 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
DE102004046236A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
GB0508924D0 (en) 2005-04-30 2005-06-08 Astrazeneca Ab New use
GB0510207D0 (en) 2005-05-19 2005-06-22 Astrazeneca Ab Novel combination
EP1894576B1 (en) 2005-06-08 2011-05-25 Kowa Company, Ltd. Novel triglyceride reducing agent
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AR057555A1 (es) 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis

Also Published As

Publication number Publication date
BRPI0713768A2 (pt) 2012-10-30
RS53084B (en) 2014-06-30
AU2007271186C1 (en) 2013-08-15
NZ594369A (en) 2013-10-25
SI2359826T1 (sl) 2014-02-28
EA200900073A1 (ru) 2009-06-30
JP2009541459A (ja) 2009-11-26
JP2013035870A (ja) 2013-02-21
US20100069392A1 (en) 2010-03-18
KR20090025368A (ko) 2009-03-10
PL2359826T3 (pl) 2014-04-30
UA101556C2 (uk) 2013-04-10
PT2359826E (pt) 2014-01-20
ME01648B (me) 2014-09-20
CY1115462T1 (el) 2017-01-04
DK2363130T3 (da) 2014-07-21
US9713614B2 (en) 2017-07-25
CN102764440A (zh) 2012-11-07
CN102772411A (zh) 2012-11-14
EP2363130B1 (en) 2014-05-07
WO2008003701A2 (en) 2008-01-10
ES2378281T3 (es) 2012-04-10
CN101484166A (zh) 2009-07-15
ZA200809905B (en) 2009-11-25
NZ603207A (en) 2013-12-20
IL221307A0 (en) 2012-09-24
UA98466C2 (uk) 2012-05-25
ATE535244T1 (de) 2011-12-15
UA106422C2 (uk) 2014-08-26
NO20090370L (no) 2009-02-04
EP2040707B1 (en) 2011-11-30
HRP20140707T1 (hr) 2014-09-12
IL221309A (en) 2014-12-31
NZ573378A (en) 2012-03-30
WO2008003701A3 (en) 2008-03-13
PL2363130T3 (pl) 2014-09-30
EP2359826A1 (en) 2011-08-24
ME01901B (me) 2014-12-20
IL195433A (en) 2013-02-28
ES2489265T3 (es) 2014-09-01
EP2359826B1 (en) 2013-10-30
CN101484166B (zh) 2012-09-05
DK2359826T3 (da) 2014-01-20
ES2443342T3 (es) 2014-02-19
CA2656366A1 (en) 2008-01-10
PT2363130E (pt) 2014-06-25
SI2363130T1 (sl) 2014-09-30
EA201401042A1 (ru) 2016-05-31
EA021461B1 (ru) 2015-06-30
IL195433A0 (en) 2009-08-03
AU2007271186A1 (en) 2008-01-10
EP2363130A1 (en) 2011-09-07
AU2007271186B2 (en) 2013-01-17
EA032476B1 (ru) 2019-06-28
RS53461B (en) 2014-12-31
JP2013035871A (ja) 2013-02-21
IL221307A (en) 2014-08-31
NO342590B1 (no) 2018-06-18
KR101433394B1 (ko) 2014-08-26
EP2040707A2 (en) 2009-04-01
US20150272949A1 (en) 2015-10-01
JP5349302B2 (ja) 2013-11-20
MX2008016123A (es) 2009-01-15
CY1114742T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
HRP20140073T1 (hr) Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
HRP20120286T1 (hr) Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
NZ600790A (en) Combination therapy for copd
HRP20131233T1 (hr) Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor
WO2006018182A8 (en) Combinations for the treatment of diseases involving cell proliferation
TW200602051A (en) Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
NO20045219L (no) Kalsitonin-gen-relaterte peptid-reseptor-antagonister
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
JP2008540486A5 (hr)
JP2009518415A5 (hr)
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2003065987A3 (en) Granzyme b inhibitors
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
WO2005079766A3 (en) Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
WO2005032470A3 (en) Compositions and methods for treating burns
EP1750703A4 (en) METHOD FOR REDUCING GASTROINTESTINAL TOXICITY BY ADMINISTRATION OF TEGAFUR
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2007000967A (es) Composiciones de risedronato y metodos para su uso.
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
SE0303480D0 (sv) Benzofuranes
WO2005120148A3 (en) Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of diseases
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
MX2018014425A (es) Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.